Free Trial
NASDAQ:BCAX

Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Bicara Therapeutics logo
$9.16 -0.28 (-3.00%)
As of 11:03 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Bicara Therapeutics Stock (NASDAQ:BCAX)

Key Stats

Today's Range
$8.98
$9.47
50-Day Range
$9.27
$15.66
52-Week Range
$7.80
$28.09
Volume
104,413 shs
Average Volume
589,736 shs
Market Capitalization
$500.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.86
Consensus Rating
Buy

Company Overview

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Bicara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

BCAX MarketRank™: 

Bicara Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 758th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bicara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Bicara Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Bicara Therapeutics' stock forecast and price target.
  • Short Interest

    There is no current short interest data available for BCAX.
  • Dividend Yield

    Bicara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Bicara Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BCAX.
  • News Sentiment

    Bicara Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for Bicara Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for BCAX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Bicara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bicara Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.50% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Bicara Therapeutics' insider trading history.
Receive BCAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCAX Stock News Headlines

Buffett’s Next Move Could Shock Wall Street
In just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next great gold rush. Savvy insiders are quietly positioning now… before Buffett makes it official. Garrett Goggin has already pinpointed four tiny-gold-miners that could 100X once the announcement hits. It’s the perfect moment to be greedy — before the herd wakes up.
See More Headlines

BCAX Stock Analysis - Frequently Asked Questions

Bicara Therapeutics' stock was trading at $17.42 at the beginning of 2025. Since then, BCAX stock has decreased by 45.8% and is now trading at $9.44.
View the best growth stocks for 2025 here
.

Bicara Therapeutics Inc. (NASDAQ:BCAX) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.28.

Bicara Therapeutics (BCAX) raised $315 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at $18.00 per share.

Top institutional shareholders of Bicara Therapeutics include Siren L.L.C. (5.99%), Vestal Point Capital LP (5.08%), Braidwell LP (3.97%) and Wellington Management Group LLP (2.56%).
View institutional ownership trends
.

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/13/2025
Today
5/29/2025
Next Earnings (Estimated)
6/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCAX
Previous Symbol
NASDAQ:BCAX
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.86
High Stock Price Target
$48.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+237.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$514.82 million
Optionable
N/A
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:BCAX) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners